Skip to main content
MRNA
NASDAQ Life Sciences

Moderna 解决了价值 22.5 亿美元的 Covid-19 疫苗专利诉讼，股价上涨

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
9
Price
$53.868
Mkt Cap
$21.275B
52W Low
$22.28
52W High
$56.6
Market data snapshot near publication time

summarizeSummary

Moderna 已同意了一项重大专利和解协议，向 Arbutus Biopharma 和 Genevant Sciences 支付高达 22.5 亿美元，以解决其 Covid-19 疫苗技术的诉讼。该协议包括 9.5 亿美元的预付款，以及根据相关上诉结果可能支付的额外 13 亿美元。这一解决方案避免了下周原定的审判，对 Moderna 来说是一个具有物质性积极发展，消除了大量的法律和财务不确定性。虽然付款金额很大，但分析师认为这避免了可能更糟糕的情况，提供了对重大负债的明确性。这是在 Moderna 最近宣布对专利纠纷前一项裁决提出上诉的消息之后，这突出了该公司持续的法律挑战，这一和解协议现在部分解决了这些问题。投资者现在将关注可能触发额外付款的上诉结果。

在该公告发布时，MRNA的交易价格为$53.87，交易所为NASDAQ，所属行业为Life Sciences，市值约为$212.7亿。 52周交易区间为$22.28至$56.60。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed MRNA - Latest Insights

MRNA
Apr 21, 2026, 9:40 AM EDT
Source: Access Newswire
Importance Score:
8
Moderna's mCOMBRIAX, World's First Flu-COVID Combo Vaccine, Gets EU Marketing Authorization
Sentiment: Positive
View Wiseek Article
MRNA
Mar 13, 2026, 6:58 AM EDT
Source: Reuters
Importance Score:
8
GSK's RSV Vaccine Gains Key FDA Approval for Younger Adults, Intensifying Competition for Moderna
Sentiment: Negative
View Wiseek Article
MRNA
Mar 04, 2026, 8:20 PM EST
Filing Type: 8-K
Importance Score:
8
Moderna Settles Patent Litigation for Up to $2.25B, Securing Royalty-Free Rights for Key Vaccines
Sentiment: Neutral
View Wiseek Article
MRNA
Mar 04, 2026, 10:10 AM EST
Source: Dow Jones Newswires
Importance Score:
9
Moderna Settles Major Covid-19 Vaccine Patent Suit for $2.25 Billion, Shares Rise
Sentiment: Positive
View Wiseek Article
MRNA
Mar 03, 2026, 4:28 PM EST
Source: Dow Jones Newswires
Importance Score:
8
Moderna to Appeal to Federal Circuit Court, Citing Government-Contractor Immunity Defense
Sentiment: Neutral
View Wiseek Article
MRNA
Mar 03, 2026, 4:25 PM EST
Source: Reuters
Importance Score:
8
Moderna Projects $4.5B-$5B Year-End Cash, Reveals $950M Q1 Settlement Charge
Sentiment: Neutral
View Wiseek Article
MRNA
Mar 03, 2026, 3:04 PM EST
Source: Wiseek News
Importance Score:
8
Moderna's Cancer Vaccine Shows Reduced Recurrence, FDA Reverses Flu Vaccine Review
Sentiment: Positive
View Wiseek Article
MRNA
Feb 27, 2026, 7:00 AM EST
Source: Acceswire
Importance Score:
8
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
Sentiment: Positive
View Wiseek Article
MRNA
Feb 20, 2026, 4:02 PM EST
Filing Type: 10-K
Importance Score:
8
Moderna Reports $2.8B Net Loss in 2025 Amidst 40% Revenue Decline, Discontinues CMV Vaccine in Congenital CMV
Sentiment: Negative
View Wiseek Article
MRNA
Feb 13, 2026, 7:02 AM EST
Filing Type: 8-K
Importance Score:
7
Moderna Reports Q4 & FY25 Results, Projects 10% Revenue Growth in 2026, Faces US Flu Vaccine Setback
Sentiment: Neutral
View Wiseek Article